| Overview |
| bsm-51398M |
| BCL10 (5C2) Monoclonal Antibody |
| WB, FCM, IHC-P, IF |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This BCL10 antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 1-143 amino acids from the human region of human BCL10. |
| Monoclonal |
| #REF! |
| IgG1 |
| 0.5ug/ul |
| Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C for 12 months. |
| Target |
| 8915 |
| O95999 |
| CLAP; mE10; CIPER; IMD37; c-E10; CARMEN; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; Cellular homolog of vCARMEN; cCARMEN; Cellular-E10; Mammalian CARD-containing adapter molecule E10; BCL10 |
| Involved in adaptive immune response (PubMed:25365219). Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1 (PubMed:18264101). |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IF |
|